Lannett Cuts Deal With Celgene In Thalomid Antitrust Case
Lannett Co. Inc. on Tuesday resolved its antitrust suit in Pennsylvania federal court alleging Celgene Corp. unfairly blocked it from launching a generic version of Celgene's thalidomide-based cancer drug Thalomid....To view the full article, register now.
Already a subscriber? Click here to view full article